创新的重新定位的瘤性疹病毒对抗nectin4阳性癌症
Andrea Vannini1,2, Federico Parenti1, Cristina Forghieri1
1Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.
Frontiers in molecular biosciences
|May 30, 2023
概括
一种新型的瘤免疫治疗性疹病毒,R-421,专门针对表达Nectin4的癌细胞,不影响正常细胞. 这种工程病毒在预临床模型中显示出降低瘤生长和提高免疫治疗疗效的前景.
科学领域:
- 在瘤学瘤学.
- 病毒学 病毒学
- 免疫治疗是一种免疫疗法.
背景情况:
- Nectin4是一种瘤抗原,在难以治疗的癌症中过度表达,如三阴性乳腺癌和胰腺癌.
- 目前的Nectin4向疗法有限,只有一种已批准的药物和少数正在进行的临床试验.
- 对抗Nectin4阳性恶性瘤的新疗法存在重大未满足的需求.
研究的目的:
- 设计和评估一种新的Nectin4特异性瘤免疫治疗性疹病毒 (R-421).
- 评估R-421在体外和体内模型中的安全性和有效性.
- 确定R-421作为独立治疗和组合疗法的治疗潜力.
主要方法:
- 设计了一种对Nectin4具有高特异性的疹病毒 (R-421),避免了天然疹病毒进入受体.
- 在实验室中评估了R-421对Nectin4阳性癌细胞和正常细胞的传染性和细胞分解活性.
- 在小鼠瘤模型中评估R-421的抗瘤疗效,安全性和免疫媒介作用.
- 研究了R-421与免疫检查点抑制剂和环胺的结合中的潜力.
主要成果:
- R-421在体外选择性地感染并杀死Nectin4阳性恶性细胞,节省正常细胞和Nectin4低表达的恶性细胞.
- 在体内,R-421显著减少或消除了Nectin4-转基因小鼠模型中的瘤生长.
- R-421与免疫检查点抑制剂和环胺胺具有协同作用,表明T细胞介导活性.
- R-421诱导在位疫苗接种,提供对远程瘤挑战的保护.
结论:
- R-421是一种高度特异且有效的Nectin4重定位的对抗免疫治疗性疹病毒.
- 这种方法提供了一种有前途的创新策略来对抗多种难以治疗的癌症.
- 这些发现支持进一步开发R-421用于临床应用在Nectin4阳性癌症中.
相关概念视频
Tumor Immunotherapy
577
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
577
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer Vaccines
437
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
437
Cancer Therapies
7.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.8K
Rous Sarcoma Virus (RSV) and Cancer
5.2K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.2K


